DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application. Here, DGAT2 is linked to metabolic dysfunction-associated steatotic liver disease.